{"contentid": 488630, "importid": NaN, "name": "Novel glaucoma med targets once-daily dosing regimen", "introduction": "Mumbai\u00e2\u0080\u0099s Sun Pharma Advanced Research Company has reported positive top-line data from a Phase III trial of investigational eye drug PDP-716.", "content": "<p>Mumbai&rsquo;s Sun Pharma Advanced Research Company (BSE: 532872; SPARC) has reported positive top-line data from a Phase III trial of investigational eye drug PDP-716.</p>\n<p>The ophthalmic suspension of brimonidine tartrate has been developed using SPARC&rsquo;s proprietary TearAct technology.</p>\n<p>The trial, which tests PDP-716 in open angle glaucoma or ocular hypertension, met its pre-specified primary endpoint, showing a once-daily dose is equivalent to three daily doses of Alphagan P (brimonidine).</p>\n<p>Equivalence in intraocular pressure was demonstrated across all nine required timepoints, showing that the two formulations of brimonidine are functionally equivalent. Data on safety were also similar.</p>\n<p>Developed by Allergan, now part of AbbVie (NYSE: ABBV), Alphagan P continues to generate revenues together with stablemate Combigan (brimonidine tartrate/timolol maleate). In 2020, AbbVie booked sales of $326 million for the two products.</p>\n<p>Other older marketed products in this area include&nbsp;Pfizer&rsquo;s (NYSE: PFE) Xalatan (latanoprost) and AbbVie's Lumigan (bimatoprost).</p>\n<p>Next-generation products for glaucoma include&nbsp;Rhopressa (netarsudil), from Aerie Pharmaceuticals (Nasdaq: AERI), and&nbsp;Vyzulta (latanoprostene bunod), developed by Nicox (Euronext: COX) and Bausch Health (TXS: BHC), both of which were first approved in 2018.</p>\n<p>Chief executive Anil Raghavan said PDP-716 &ldquo;can significantly reduce the dosing frequency compared to the currently marketed formulation and can have a positive impact on quality of life for patients with glaucoma.&rdquo;</p>\n<p>Formed in 2007 through a demerger from Sun Pharma, SPARC aims to provide innovative medicines using &ldquo;high value analytics and aggressive portfolio management.&rdquo;</p>\n<p>The company is also focused on lowering costs to improve availability and affordability of medicines on a global basis.</p>\n<p>SPARC currently offers Xelpros (latanoprost), a novel, translucent treatment for open angle glaucoma or ocular hypertension, developed with Lipixelle technology.</p>\n<p>The firm's other marketed product is Elepsia XR (levetiracetam), a higher dose anti-epileptic enabling once-daily administration.</p>", "date": "2021-05-14 11:05:00", "meta_title": NaN, "meta_keywords": "glaucoma, PDP-, once-daily, trial, brimonidine, data, positive, company, Pharma, dosing, eyes, regimen, Research, drug, reported, investigational, topline", "meta_description": "Mumbai\u00e2\u0080\u0099s Sun Pharma Advanced Research Company has reported positive topline data from a Phase III trial of investigational eye drug PDP-716.", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-05-14 09:43:00", "updated": "2021-05-14 11:35:37", "access": NaN, "url": "https://www.thepharmaletter.com/article/novel-glaucoma-med-eyes-once-daily-dosing-regimen", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "sparc_big.jpg", "image2id": "sparc_small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Pharmaceutical", "therapy area_tag": "Ophthalmics", "topic_tag": "Drug Trial, Research", "geography_tag": "India", "company_tag": "AbbVie, SPARC, Sun Pharma Advanced Research Company", "drug_tag": "Alphagan-P, PDP-716", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-05-14 11:05:00"}